Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives

Front Endocrinol (Lausanne). 2023 Aug 2:14:1238927. doi: 10.3389/fendo.2023.1238927. eCollection 2023.

Abstract

Diabetic kidney disease (DKD) is a chronic complication of diabetes and the leading cause of end-stage renal disease (ESRD) worldwide. Currently, there are limited therapeutic drugs available for DKD. While previous research has primarily focused on glomerular injury, recent studies have increasingly emphasized the role of renal tubular injury in the pathogenesis of DKD. Various factors, including hyperglycemia, lipid accumulation, oxidative stress, hypoxia, RAAS, ER stress, inflammation, EMT and programmed cell death, have been shown to induce renal tubular injury and contribute to the progression of DKD. Additionally, traditional hypoglycemic drugs, anti-inflammation therapies, anti-senescence therapies, mineralocorticoid receptor antagonists, and stem cell therapies have demonstrated their potential to alleviate renal tubular injury in DKD. This review will provide insights into the latest research on the mechanisms and treatments of renal tubular injury in DKD.

Keywords: diabetic kidney disease; mechanism; programmed cell death; stem cell; therapy; tubular injury.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Diabetes Mellitus*
  • Diabetic Nephropathies* / etiology
  • Diabetic Nephropathies* / therapy
  • Humans
  • Hyperglycemia*
  • Hypoglycemic Agents
  • Kidney Failure, Chronic*

Substances

  • Hypoglycemic Agents

Grants and funding

This research was funded by China International Medical Foundation, PROJECT ENDOCRINE AND METABOLIC TALENT RESEARCH, grant number 2022-N-02-14.